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cross over to active treatment at disease progression is a common
strategy to address ethical issues associated with placebo controls but
may lead to statistical challenges in the analysis of overall survival
and cost-effectiveness because crossover leads to information loss
and dilution of comparative clinical efﬁcacy. Objectives: We provide
an overview of how to address crossover, implications for risk-effect
estimates of survival (hazard ratios) and cost-effectiveness, and how
this inﬂuences decisions of reimbursement agencies. Two case stud-
ies using data from two phase III sunitinib oncology trials are used as
illustration. Methods: We reviewed the literature on statistical meth-
ods for adjusting for crossover and recent health technology assess-
ment decisions in oncology. Results: We show that for a trial with a
high proportion of crossover from the control arm to the investiga-
tional arm, the choice of the statistical method greatly affects
treatment-effect estimates and cost-effectiveness because the rangeee front matter Copyright & 2014, International S
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With relatively frequent crossover, one should consider either the
inverse probability of censoring weighting or the rank-preserving
structural failure time model to minimize potential bias, with choice
dependent on crossover characteristics, trial size, and available data.
A large proportion of crossover favors the rank-preserving structural
failure time model, while large sample size and abundant information
about confounding factors favors the inverse probability of censoring
weighting model. When crossover is very infrequent, methods yield
similar results. Conclusions: Failure to correct for crossover may lead
to suboptimal decisions by pricing and reimbursement authorities,
thereby limiting an effective drug’s potential.
Keywords: cost effectiveness, crossover, oncology, sunitinib, surviva.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Allowing patients the opportunity to switch to investigational
therapy after the primary end point has been reached is a
common strategy used to address ethical issues with the use of
placebo-controlled randomized trials. This is common practice in
oncology trials, often mandated by investigators, patients, and
ethics committees [1]. Crossover can also occur when a trial is
prematurely unblinded; for example, when an interim analysisshows a signiﬁcant gain in the primary end point of the inves-
tigational treatment or if an active treatment (control or inves-
tigational) is less safe than its comparator. In each case, crossover
results in loss of information about what the clinical effect would
have been in the absence of crossover. A direct consequence of
crossover is that standard statistical methods, for example, the
intent-to-treat (ITT) analysis, may provide biased estimates of
key end points such as overall survival (OS), for instance, and
underestimation of the true effect. Furthermore, per protocolociety for Pharmacoeconomics and Outcomes Research (ISPOR).
overall survival in randomized controlled trials with cross-over.
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 0 7 – 7 1 3708analysis (excluding patients who cross over to investigational
treatment) can be subject to selection bias because those who
switch from placebo to investigational treatment may not be
representative of the entire placebo group. Design solutions such
as randomizing crossover can be considered to minimize the
impact of crossover [2] but will seldom be feasible and have rarely
been implemented in practice. A more common approach is to
adjust for crossover effects in the statistical analysis.
Crossover is also of concern in health economics and outcomes
research because of its potential to affect estimates of efﬁcacy and
cost-effectiveness (CE). If an investigational drug reduces mortality,
ITT analysis will underestimate the treatment effect in the pres-
ence of crossover and will likely lead to an overestimate of the
incremental cost-effectiveness ratio (ICER). As a result, the deci-
sions by pricing and reimbursement agencies regarding access to
new therapies may not maximize health outcomes with the
available resources if crossover is not corrected for.
In this article, directed toward policymakers, health care
providers, health technology assessment agencies, and the phar-
maceutical industry, we review available standard and advanced
statistical methods for analyzing OS data in the presence of
crossover and discuss choice of methodology. We illustrate
differences between four methods with two case studies based
on clinical trials in two indications for sunitinib (Sutent; Pﬁzer,
Inc., New York, NY), an orally administered, multitargeted tyro-
sine kinase inhibitor, which is approved in several countries for
the treatment of metastatic renal cell carcinoma (mRCC) and
imatinib-resistant gastrointestinal stromal tumor (GIST) [3–8].
Both trials showed statistically signiﬁcant beneﬁt in pro-
gression-free survival (PFS) for sunitinib, and each illustrates a
different situation regarding crossover. In the mRCC trial, cross-
over was infrequent and allowed only after overwhelming PFS
results were observed [7], whereas in the GIST trial, crossover was
frequent and allowed because of the placebo control design [4,9].
As we shall see, the two cases lead to interesting and potentially
instructive differences in the use and outcomes of the four
methods with respect to estimated treatment beneﬁts and cost-
effectiveness.Statistical Analysis of Trials with Crossover
Statistical methods that are used to evaluate OS can be grouped
into simple methods, which make no speciﬁc attempts to address
crossover, and advanced methods based on statistical modeling
techniques, which attempt to eliminate or reduce bias due to
crossover.
Simple Methods
ITT analysis
In the standard ITT analysis, data for all randomized subjects are
included for the entire period of observation. This method is
appropriate as long as the aim is to compare one planned
treatment with another irrespective of any subsequent treatment
changes. If an investigational drug has a true mortality beneﬁt,
however, the ITT analysis will underestimate OS in the presence
of crossover, and a cost-effectiveness analysis based on these
data will likely overestimate the ICER of the new therapy [10].
Censoring at crossover (on-treatment analysis)
Censoring patients at crossover eliminates observations of
patients randomized to the control arm after they receive the
investigational treatment. Two disadvantages of the censoring
method are selection bias and loss of power. Unless the proba-
bility of crossover is random, censoring may introduce bias,
because events that result in censoring (e.g., progressive disease)may likely be associated with the ﬁnal outcome (e.g., death) [2].
Censoring therefore leads to underestimation of gains in OS with
the investigational treatment and selective exclusion of patients
with a high probability of death. Censoring also lowers the power
of the study because of shorter overall observation time and a
reduced number of observed events in the control arm.
The potential selection bias induced by censoring can be
reduced or eliminated if crossover is determined by random-
ization or if the entire control group crosses over to the investiga-
tional treatment at a prespeciﬁed point in time [2]. Even in these
situations, however, censoring still reduces the statistical power
of the study.
Statistical Modeling
During the last two decades, statistical modeling techniques have
been developed to adjust for weaknesses in observational and
clinical trial data. There is no criterion standard because the
methods have different strengths and weaknesses. Two methods
that have recently been used to attempt to correct for crossover
in oncology trials are the inverse probability of censoring weight-
ing (IPCW) model and the rank-preserving structural failure time
(RPSFT) model. These apply statistical modeling techniques to
reconstruct data for the control arm as if crossover had not
occurred, with the aim of reducing bias and allowing the treat-
ment effect to be assessed more accurately. Results based on
these methods have been considered as relevant by health
technology assessment bodies such as the National Institute for
Health and Care Excellence (NICE) in the United Kingdom [11] and
the Dental and Pharmaceutical Beneﬁts Agency (tandvårds-och
läkemedelsförmånsverket) in Sweden [12].
The IPCW model
The IPCW model is frequently used in epidemiologic research to
adjust for nonrepresentative sampling or dropouts. In this
method, patients who cross over from control to investigational
treatment are censored, while patients remaining in the control
arm are weighted to compensate for missing data [13]. The bias
introduced by this informative crossover is corrected by weight-
ing each patient by the inverse of his or her predicted probability
of not being censored at a given time. The ﬁrst step in the IPCW
analysis is to predict the probability of crossover on the basis of
each patient’s baseline characteristics, such as age, sex, race, or
biological markers [13–15], often by ﬁtting a logistic regression
model. Finally, OS is analyzed with the censored data set and
observations weighted by the inverse of the predicted probability
of censoring.
The IPCW model assumes that the probability of crossover at
a given time depends only on observed covariates and must be
independent of the outcome and its timing [13]. If these assump-
tions hold, then censoring can be made noninformative through
the IPCW model. The clinical trial data must contain enough
information about the covariates that affect the probability of
crossover.
The RPSFT model
The RPSFT model allows a direct comparison of randomization
groups by adjusting the OS of patients who cross over so that it
reﬂects the OS had they not received the investigational treat-
ment. The method is related to the accelerated failure time model
in OS analysis [16,17], in which prognostic variables measured on
the individual level are assumed to act multiplicatively on the
time scale, for example, affecting the rate of progression. The ﬁrst
step is to deﬁne a causal model relating the observed event time T
to the unobserved event time U that would have been observed if
crossover had not occurred. This is performed by assuming that T
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 0 7 – 7 1 3 709and U are related by a constant acceleration factor, exp(ψ), which
is equal for all patients who cross over:
Ti¼TioffþTion,
Ui¼Tioffþexp ψð ÞTion,
where Ti is the total observed time on control therapy, Ti
on is the
observed time on treatment, Ti
off is the observed time off treat-
ment, and Ui is the time that would have been observed if
crossover had not occurred. The parameter ψ, the causal effect
of treatment on OS, is estimated through G-estimation, whereby
U is computed for a range of possible values of ψ and ﬁnding the
value for which a log-rank test of the equality of U across the two
groups has the highest P value [16]. The second step is to perform
the OS analysis on the data set after OS has been adjusted (Ui
values) for crossover cases in the control group. Event times that
fall beyond the time horizon of the study need to be censored, a
process referred to as recensoring.
The RPSFT model is rank preserving because a constant factor
is used for adjusting the time to event for each patient [16]. Thus,
if two patients i and j are on the same treatment (either control or
crossover), and patient i fails (dies) before patient j, before
adjustment, patient i will also always fail before patient j after
adjustment: the ranking in failure times is preserved. The model
is structural (causal) in the sense that it assumes a deﬁned
relationship between the observed event time and the event
time that would have been observed if crossover had not
occurred [10].
A key assumption of the RPSFT model is that the investiga-
tional treatment causes a constant reduction in time to death,
assumed equal for all patients before and after progression. This
may be a reasonable assumption in some cases but not in others,
which may restrict the use of the method to cases in which a
constant proportional reduction in the time to event is biolog-
ically plausible.
Other methods
There are additional statistical methods that could prove useful
in analyzing randomized trials with crossover. Structural nested
mean models [18] can be useful for trials in which the primary
end point is a measurement (e.g., mm Hg) rather than an event
rate. State-transition probability modeling [19] has been used to
analyze observational data with time-dependent effects and
could potentially be adapted to address the issue of crossover
in randomized trials.Fig. 1 – Hazard ratios (with 95% conﬁdence intervals) for overall
patients with metastatic renal cell carcinoma using four different
there was a low rate of crossover (7%) [7]. *The structural metho
95% conﬁdence intervals were estimated using nonparametric b
analysis. IPCW, inverse probability of censoring weighting; ITT, iCase Studies
Case 1. Sunitinib in mRCC
In an international phase III trial, 750 patients with mRCC were
randomized to receive either sunitinib (n ¼ 375) or interferon-alfa
(IFN-α; n ¼ 375) [6,7]. Crossover was allowed only after an interim
analysis had concluded a signiﬁcant gain in the primary end
point PFS. Twenty-ﬁve patients (7%) in the IFN-α group crossed
over to sunitinib after an average of 70.8 weeks. Although
relatively low, the amount of crossover could still potentially
affect results.
There were 390 deaths in total: 190 in the sunitinib and 200 in
the IFN-α arm, respectively. All events were included in the ITT
analysis, while censoring at the time of crossover led to the
exclusion of ﬁve deaths in the IFN-α arm occurring after the
switch to sunitinib. The IPCW model used progressive disease,
male gender, young age, and nephrectomy as covariates for
estimating the propensity scores for crossover. All four covariates
signiﬁcantly increased the risk of crossover. In the RPSFT model,
the estimated value for the acceleration parameter ψ using a grid
search method was 0.244, corresponding to a decrease in the OS
time by 1  exp(ψ) ¼ 22% with IFN-α than with sunitinib.
The hazard ratios (HRs) for OS between the experimental
treatment and control for the four different methods of handling
crossover ranged between 0.807 and 0.821 (Fig. 1), their similarity
explained by limited crossover in the trial. As expected, the ITT
method produced the highest HR because the effect of sunitinib
on OS was included in both arms. Compared with censoring at
crossover, the IPCW resulted in a slightly lower HR estimate, but a
somewhat wider conﬁdence interval (CI) due to the additional
uncertainty introduced by the estimation of inverse probability
weights. The slightly lower HR with the RPSFT indicates that OS
after crossover was slightly better than “expected” for patients in
the IFN-α arm, but the difference was small.
The CE of sunitinib in mRCC was evaluated by NICE [20].
Applying the manufacturer’s model, the ITT method yielded an
expected OS of 163 versus 136 weeks for sunitinib versus IFN-α
and an ICER of £72,000/quality-adjusted life-year (QALY) (Table 1).
Censoring at crossover provided an ICER of £71,760/QALY [21].
Structural models were not used for the evaluation. Applying the
RPSFT adjustment changed the incremental OS gain with suniti-
nib only marginally (by o1 week) and similarly reduced the
ICER only marginally to £71,850/QALY. NICE ﬁnally based itssurvival with sunitinib compared with interferon-alfa in
statistical methods to account for crossover; in this example,
d estimates were not adjusted for poststudy treatment, and
ootstrapping. No recensoring was performed in the RPSFT
ntent-to-treat; RPSFT, rank-preserving structural failure time.
Table 1 – Methods for crossover adjustment and
corresponding incremental cost-effectiveness
ratios (ICERs) in GBP.
Method mRCC GIST
ITT (no crossover adjustment)
Overall survival beneﬁt (wk) 27 8
Cost per QALY (£) 72,000 90,500
RPSFT
Overall survival beneﬁt (wk) 28 34
Cost per QALY (£) 71,850 31,800
NICE estimate o50,000 31,800
GIST, gastrointestinal stromal tumor; ITT, intent-to-treat; mRCC,
metastatic renal cell carcinoma; NICE, National Institute for Health
and Care Excellence; QALY, quality-adjusted life-year; RPSFT,
rank-preserving structural failure time.
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for a subset of the population that did not receive any poststudy
treatment (including crossover) with estimated ICER below the
£50,000 threshold.
Case 2. Sunitinib in GIST
An international phase III study randomized 361 patients with
GIST in a 2:1 ratio to sunitinib (n ¼ 243) or placebo with best
supportive care (n ¼ 118) [4,9]. Crossover was allowed in the
protocol at documented progression, and additional crossover
was allowed as a result of early recommended unblinding due to
longer time to progression for sunitinib.
A total of 103 patients (87%) in the placebo group crossed over
to sunitinib. The median time to progression for the ITT placebo
population was 6.4 weeks (95% CI 4.4–10.0). Patients crossed over
on average 4.1 weeks after progression (range 1 day to 32 weeks;
the negative lower value is due to potential discrepancies in the
date of progression as determined by central reading and the
investigator). A total of 266 patients died: 90 in the placebo arm
and 176 in the sunitinib arm (2:1 randomization).
The HRs for OS between experimental treatment and control
for the three different methods of handling crossover ranged
from 0.505 to 0.876 (Fig. 2). Censoring at the time of crossover led
to the exclusion of 77 events in the placebo arm, with only 13
events remaining for the OS analysis. Calculating a CoxFig. 2 – Hazard ratios (with 95% conﬁdence intervals) for overall
with gastrointestinal stromal tumor using three different statist
was a high rate of crossover (87%) [9]. *The structural method es
conﬁdence intervals were estimated using nonparametric boots
structural failure time.regression based on only 13 events leads to considerable uncer-
tainty, as reﬂected by the 95% CI stretching from 0.454 to 1.499
(HR ¼ 0.825).
There was a high proportion of crossover in the trial; out of 73
patients in the placebo group whose disease progressed, 69
crossed over to sunitinib. Because disease progression was
strongly correlated with crossover (P o 0.001), and also with the
ﬁnal outcome of death, the simple censored analysis leads to
bias. In the RPSFT model, the estimated value for the acceleration
parameter ψ, using a grid search method [10], was equal to
0.656. The resulting HR for OS comparing sunitinib with placebo
after recensoring was estimated at 0.505 [22]. The IPCW model
could not be applied in this case because the number of remain-
ing events after censoring was too few (2 in the placebo group).
Again, the ITT method produced the most conservative efﬁcacy
estimate. Censoring at crossover gave a lower HR with wider CIs
because all the information on OS after crossover was discarded.
The RPSFT model yielded the most favorable HR, although it fell
short of statistical signiﬁcance. The substantial difference in the
point estimate compared with the ITT analysis indicates that OS
was improved after crossover; however, the uncertainty introduced
by the RPSFT model was illustrated by wider CIs.
The CE of sunitinib in GIST was evaluated by NICE [23]. The
base-case analysis used the RPSFT model, which yielded an
expected OS of 73 weeks versus 39 weeks for sunitinib compared
with placebo with best supportive care and an ICER of £31,800/
QALY (Table 1). In contrast, the ITT method showed an ICER of
£90,500/QALY with an expected OS of 65 weeks for patients on
placebo with best supportive care without adjusting for cross-
over. Thus, the RPSFT adjustment changed the incremental OS
gain with sunitinib from 8 to 34 weeks and substantially reduced
the ICER. Based on the results from the RPSFT model, NICE
recommended sunitinib for use in GIST.Other examples
Other recent examples of economic evaluations based on trials
with substantial crossover showed similar differences between
estimated OS gains and CE when crossover was corrected for with
the use of structural models. In the pivotal trial VEG105192 of
pazopanib versus placebo in mRCC, 40 of 78 (51%) patients in the
placebo arm had crossed over to pazopanib at the time of the
ﬁnal analysis [24,25]. The economic evaluation undertaken for
NICE, a development of the RPSFT model, which used weighted
log-rank tests rather than the standard unweighted test tosurvival with sunitinib compared with placebo in patients
ical methods to account for crossover; in this example, there
timates were not adjusted for poststudy treatment, and 95%
trapping. ITT, intent-to-treat; RPSFT, rank-preserving
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mortality), showed an HR of 0.627 and an ICER of £38,925 for
pazopanib versus IFN-α. For comparison, censoring at crossover
resulted in an ICER of £71,648, while the IPCW model gave a cost
of £72,274 per QALY. With ITT analysis, pazopanib was domi-
nated by placebo, showing a slightly lower OS (HR ¼ 1.01; 95% CI
0.72–1.42) at a higher cost. Based on these results, pazopanib was
recommended for use in mRCC [24,25].
In the RECORD-1 trial of everolimus versus placebo in mRCC,
81% of the patients in the placebo arm had crossed over to
everolimus by the time of the analysis. In the economic evalua-
tion undertaken for NICE, the IPCW model resulted in an ICER of
£52,684/QALY and the RPSFT model in £51,700/QALY, while the
ITT analysis produced an ICER of £91,256/QALY. Everolimus has,
however, not been recommended for treatment in the United
Kingdom because the threshold level of £50,000 was exceeded
and there was uncertainty around the ICER [11].Discussion
The presence of crossover in clinical trials can invalidate stand-
ard calculations of gains in life expectancy and incremental CE.
Because ethical reasons for permitting crossover can take prece-
dence over statistical considerations, valid and accepted meth-
ods, such as the RPSFT and IPCW models, are needed to handle
the statistical issues raised by crossover and nonrandom differ-
ences in postprogression treatment.
The example of sunitinib in GIST showed that crossover and
the method to adjust for this problem can have a substantial
impact on estimates of incremental OS gains and on estimates of
CE. The ITT method underestimates the OS beneﬁt of treatment in
the presence of crossover, and CE is thereby typically underesti-
mated, although other factors such as the utility and costs
associated with end-of-life health states, the speciﬁc model design,
and other assumptions will affect the overall impact on the ICER.
The variation in the HR for OS by method of analysis was more
pronounced in the GIST trial than in the mRCC trial, which was
expected given the greater frequency of crossover in the GIST trial.
There are few other options available to assess the impact on
OS by a new therapy than to make best use of the randomized
clinical trial data, even though it is limited by crossover. Extrap-
olating from intermediate end points such as PFS is problematic;
the relationship between PFS and OS may be unknown or variable
depending on the availability and efﬁcacy of downstream thera-
pies. Conducting additional placebo-controlled studies is usually
not possible from an ethical perspective. Prospective observatio-
nal studies, use of data from earlier trials [26], and retrospective
database studies offer possible alternatives but have other lim-
itations, and data may not be available at the time that reim-
bursement decisions are made.
There is limited experience with how reimbursement agen-
cies view crossover; agencies have yet to issue speciﬁc methodo-
logic guidance. In the NICE appraisal of sunitinib for GIST, the
RPSFT model was accepted as appropriate, although this was also
identiﬁed as an area of concern. The consistency of the HR for OS
during the period before crossover (0.49) with the RPSFT estimate
(0.505) strengthened the conﬁdence in this method [22]. Decisions
on pazopanib and everolimus show an increased reliance on
applying the crossover methods by NICE over time. Similarly, the
Swedish reimbursement agency (tandvårds-och läkemedelsför-
månsverket) has acknowledged structural methods, although
little information is available regarding its speciﬁc views on these
methods [12].
Some reimbursement agencies, however, seem more skeptical.
The pan-Canadian Oncology Drug Review issued a recommenda-
tion regarding pazopanib in mRCC, stating that “The Committeediscussed that it would be difﬁcult to obtain statistically signiﬁcant
OS results given the high rate of cross-over in the placebo arm of
the trial” [27]. No reference was made to the RPSFT estimate
provided in the funding application, which may indicate that the
committee did not consider this as relevant evidence. In the
reviews of the Australian Pharmaceutical Beneﬁts Advisory Com-
mittee (PBAC) of sunitinib in the GIST trial, the OS estimate for the
placebo group was considered highly uncertain because it repre-
sented a modeled estimate [28]. Reviewing everolimus for mRCC,
the PBAC considered that the main area of uncertainty was in the
estimation of OS within the study using the IPCW model, in
particular regarding the reweighting of individuals in the placebo
arm. The PBAC also found that estimates using IPCW and RPSFT
models were confounded by design limitations of the RECORD-1
study, which permitted early and extensive crossover [29].
The choice of method for handling crossover is important and
depends on several factors related to the treatments under study,
the trial design, the frequency and timing of crossover (gradually,
such as on patient progression, vs. all at once, such as after early
unblinding), the OS time after progression, and whether assump-
tions behind statistical modeling methods are fulﬁlled.
Ignoring crossover or using simple methods such as censoring
at crossover likely produces biased estimates and can be accept-
able only with very low frequency of crossover, and when
combined with a statistical modeling method as a sensitivity
analysis. If crossover is frequent, a statistical modeling method is
recommended as the base-case analysis. However, no single
method completely solves the missing data problem and there
is no consensus or guidance on the choice of the method to
analyze OS data from trials with crossover, although various
alternatives have been used in previously published studies
[10,13–15,30,31]. The models are complex and allow variability
in implementation, such as the regression speciﬁcation in the
IPCW model and the approach taken to RPSFT modeling [32]. The
performance of the methods can be tested by using Monte-Carlo
simulation: the predictive performance of the RPSFT and IPCW
models might, for example, be tested by randomly excluding a
number of patients from both arms of a trial and seeing which
results correspond most closely to true values [33].
Advantages of the RPSFT model include using the complete data
set of patients in the trial and that ranking of the observed time-to-
event data is preserved after adjustment. Limitations include the
fact that the method does not use information on patient cova-
riates, which may affect the probability of crossover, although this
can be amended in more complex RPSFT models. Finally, the
assumption that mortality decreases constantly during the time
that the investigational drug is received may not reﬂect reality. The
IPCWmodel, however, uses only those patients who have not been
censored by crossover, which may lead to an unacceptable loss of
power, as in the GIST example. The method is data-demanding if it
is to give reliable results because adjustment is based entirely on
observed covariates. For these reasons, the IPCW model may be
most appropriate in trials with a relatively large sample size, in
which only a moderate proportion of patients cross over and which
have sufﬁcient information regarding potential confounding fac-
tors. The RPSFT model would be preferable for smaller trials with
relatively little information on covariates, and is also suitable for
trials in which a large proportion of patients cross over, when the
assumption about proportionality of the treatment effect on OS can
be justiﬁed.
Table 2 provides a summary of considerations when choosing
the appropriate method to adjust for crossover under different
circumstances regarding degree of crossover, trial size, and
availability of data on confounders. This is based largely on
theoretical considerations and is supported by only limited
empirical evidence; further research is needed to provide recom-
mendations regarding the choice of analysis in different
Table 2 – Considerations for selecting method to
analyze overall survival in the presence of cross-
over according to trial type and availability of data.
Consideration Crossover
at random*
Crossover not
at random
Few patients cross over ITT IPCW
Many patients cross over ITT or RPSFT RPSFT
Small trial ITT or RPSFT RPSFT
Large trial ITT or RPSFT IPCW
Little information on
confounding factors
ITT or RPSFT RPSFT
Abundant information on
confounding factors
ITT or RPSFT IPCW
IPCW, inverse probability of censoring weighting; ITT, intent-to-
treat; RPSFT, rank-preserving structural failure time.
* Crossover at random means that crossover is independent of
patient characteristics and prognostic factors that are correlated
with survival
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 0 7 – 7 1 3712situations. When crossover is very infrequent, methods can be
expected to yield similar results. In this case, the argument can
be made for retaining an ITT analysis.
Finally, the analysis method(s) to adjust for crossover should
be prespeciﬁed in the statistical analysis plan, including an
algorithm for method selection and inclusion of covariates, to
avoid bias associated with post hoc analyses. We recommend
applying several methods, with one prespeciﬁed as the main
option and the others as sensitivity analyses.
Crossover is one of several problems that limit the analysis of
OS in trials with PFS as the primary end point. Other issues
include insufﬁcient follow-up time leading to low power, changes
in supportive care over time, and protocol-driven changes in
postprogression treatment.
We have presented two of the main methods to address the
issue of crossover, each using available data from a trial to make
predictions about the true effect on OS. We recommend that
these methods be used routinely, both to report trial outcomes
and as building blocks in subsequent economic evaluations based
on these trials. By reducing bias and loss of power, the methods
can inform pricing and reimbursement decisions and ultimately
help optimize patient access to innovative therapies.Acknowledgments
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